GLP-1 Agonists Show Biopsy-Confirmed MASH Resolution; FDA Grants Accelerated Approval
GLP-1 receptor agonists, the drug class behind semaglutide, are now showing biopsy-confirmed benefits in MASH, the inflammatory form of fatty liver disease, with a 72-week trial reporting resolution in 62.9% … Read More